Invokana a Growing concern for Janssen

Introduction

J&J's Janssen Pharmaceuticals has more than 800 product liability cases across the nation for its anti-diabetic drug Invokana. This news is confirmed by J&J's quarterly financial filing with the Securities and Exchange Commission (SEC). The Invokana cases are consolidated as a part of an MDL before U.S. District Judge Brian Martinotti in the District of New Jersey and the trials for a small number of bellwether cases are expected to begin in September 2018. Apart from this, several federal cases are pending in the Southern District of California and the Eastern District of Missouri, as well as state court cases, are pending in California, New Jersey, and Pennsylvania. Allegations mainly involve kidney failure, heart attacks, and diabetic ketoacidosis, with a recent addition of increased risk of leg or foot amputations following a warning released by the FDA in May 2017.

Comments

Supreme Court Upholds Flavored Vape Ban

Categories: E-Cigarette: JUUL

The U.S. Supreme Court has unanimously upheld a decision by the Food and Drug Administration (FDA) to block the sale and marketing of certain flavored e-cigarette products.

The ruling supports the FDA’s authority to regulate tobacco…

Judge Rejects JnJ's $10B Talc Lawsuit Settlement

Categories: Talcum

Johnson & Johnson's shares fell more than 5% after a U.S. bankruptcy judge rejected its $10 billion settlement proposal aimed at resolving over 60,000 lawsuits.

These lawsuits allege that the company’s…

Tepezza Hearing Loss MDL: Bellwether Trials Set for 2026

Categories: Tepezza

A U.S. District Judge overseeing Tepezza hearing damage lawsuits nationwide has scheduled four bellwether trials for 2026. These trials are intended to help both parties assess how juries may respond to the evidence and testimonies that could be…

Invokana a Growing concern for Janssen